Results 191 to 200 of about 184,471 (381)

Investigating Dopamine Replacement–Associated Fluctuations in Cognition and Mood in Cognitively Unimpaired Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor fluctuations, characterized by variability in mood and cognition, are prevalent in advanced Parkinson's disease (PD), but less is known about these fluctuations in early PD. Objective The objective was to characterize fluctuations in cognition and mood in early PD without cognitive impairment.
Abhimanyu Mahajan   +4 more
wiley   +1 more source

Treatment Selection and Prioritization for the EJS ACT‐PD MAMS Trial Platform

open access: yesMovement Disorders, EarlyView.
Abstract Background There are currently no disease‐modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT‐PD) initiative will expedite clinical assessment of putative DMTs through a multi‐arm multistage (MAMS) trial, testing several treatments against a common ...
Cristina Gonzalez‐Robles   +29 more
wiley   +1 more source

Recent Developments in the Optical Control of Adrenergic Signaling

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Adrenoceptors (ARs) play a vital role in various physiological processes and are key therapeutic targets. The advent of optical control techniques, including optogenetics and photopharmacology, offers the potential to modulate AR signaling with precise temporal and spatial resolution. In this review, we summarize the latest advancements in the
Shuang Shi   +4 more
wiley   +1 more source

Progress in Molecular Imprinting—From Inhibition of Enzymatic Activity to Regulation of Cellular Pathways

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Molecular imprinting is a very powerful tool in life science. The research areas benefiting from a wide range of capabilities of molecularly imprinted polymeric nanoparticles (nanoMIPs) include sample preparation, extraction, sensing/detection, diagnostics, and drug delivery.
Milada Vodova   +2 more
wiley   +1 more source

Enhancing Heart Health: Expanding the Use of SGLT2 Inhibitors in Cardiovascular Disease

open access: yesMedicine Advances, EarlyView.
SGLT2 inhibitors offer multifaceted cardiovascular benefits, including improved cardiac metabolism, reduced preload and afterload, and decreased myocardial infarction risk. These effects are driven by renoprotection, anti‐inflammatory properties, improved mitochondrial function, osmotic diuresis, and glycemic control. Together, these mechanisms support
Manahil Mubeen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy